Cargando…
Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System
The enclosed work focuses on the construction variables associated with a dual-antigen liposomal carrier, delivering encapsulated polysaccharides and surface-localized proteins, which served as a vaccine delivery device effective against pneumococcal disease. Here, the goal was to better characteriz...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747791/ https://www.ncbi.nlm.nih.gov/pubmed/31480544 http://dx.doi.org/10.3390/ma12172809 |
_version_ | 1783451975497547776 |
---|---|
author | Nayerhoda, Roozbeh Hill, Andrew Beitelshees, Marie Jones, Charles Pfeifer, Blaine |
author_facet | Nayerhoda, Roozbeh Hill, Andrew Beitelshees, Marie Jones, Charles Pfeifer, Blaine |
author_sort | Nayerhoda, Roozbeh |
collection | PubMed |
description | The enclosed work focuses on the construction variables associated with a dual-antigen liposomal carrier, delivering encapsulated polysaccharides and surface-localized proteins, which served as a vaccine delivery device effective against pneumococcal disease. Here, the goal was to better characterize and compare the carrier across a range of formulation steps and assessment metrics. Specifically, the vaccine carrier was subjected to new methods of liposomal formation, including alterations to the base components used for subsequent macromolecule encapsulation and surface attachment, with characterization spanning polysaccharide encapsulation, liposomal size and charge, and surface protein localization. Results demonstrate variations across the liposomal constructs comprised two means of surface-localizing proteins (either via metal or biological affinity). In general, final liposomal constructs demonstrated a size and zeta potential range of approximately 50 to 600 nm and −4 to −41 mV, respectively, while demonstrating at least 60% polysaccharide encapsulation efficiency and 60% protein surface localization for top-performing liposomal carrier constructs. The results, thus, indicate that multiple formulations could serve in support of vaccination studies, and that the selection of a suitable final delivery system would be dictated by preferences or requirements linked to target antigens and/or regulatory demands. |
format | Online Article Text |
id | pubmed-6747791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67477912019-09-27 Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System Nayerhoda, Roozbeh Hill, Andrew Beitelshees, Marie Jones, Charles Pfeifer, Blaine Materials (Basel) Article The enclosed work focuses on the construction variables associated with a dual-antigen liposomal carrier, delivering encapsulated polysaccharides and surface-localized proteins, which served as a vaccine delivery device effective against pneumococcal disease. Here, the goal was to better characterize and compare the carrier across a range of formulation steps and assessment metrics. Specifically, the vaccine carrier was subjected to new methods of liposomal formation, including alterations to the base components used for subsequent macromolecule encapsulation and surface attachment, with characterization spanning polysaccharide encapsulation, liposomal size and charge, and surface protein localization. Results demonstrate variations across the liposomal constructs comprised two means of surface-localizing proteins (either via metal or biological affinity). In general, final liposomal constructs demonstrated a size and zeta potential range of approximately 50 to 600 nm and −4 to −41 mV, respectively, while demonstrating at least 60% polysaccharide encapsulation efficiency and 60% protein surface localization for top-performing liposomal carrier constructs. The results, thus, indicate that multiple formulations could serve in support of vaccination studies, and that the selection of a suitable final delivery system would be dictated by preferences or requirements linked to target antigens and/or regulatory demands. MDPI 2019-09-01 /pmc/articles/PMC6747791/ /pubmed/31480544 http://dx.doi.org/10.3390/ma12172809 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nayerhoda, Roozbeh Hill, Andrew Beitelshees, Marie Jones, Charles Pfeifer, Blaine Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System |
title | Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System |
title_full | Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System |
title_fullStr | Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System |
title_full_unstemmed | Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System |
title_short | Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System |
title_sort | design variation of a dual-antigen liposomal vaccine carrier system |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747791/ https://www.ncbi.nlm.nih.gov/pubmed/31480544 http://dx.doi.org/10.3390/ma12172809 |
work_keys_str_mv | AT nayerhodaroozbeh designvariationofadualantigenliposomalvaccinecarriersystem AT hillandrew designvariationofadualantigenliposomalvaccinecarriersystem AT beitelsheesmarie designvariationofadualantigenliposomalvaccinecarriersystem AT jonescharles designvariationofadualantigenliposomalvaccinecarriersystem AT pfeiferblaine designvariationofadualantigenliposomalvaccinecarriersystem |